03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
23:02 , Dec 22, 2017 |  BC Extra  |  Company News

Management tracks: CRISPR, Hua

Gene editing company CRISPR Therapeutics AG (NASDAQ:CRSP) appointed Rodger Novak as chairman of the board. He succeeds Tony Coles, who will remain as a senior adviser. Novak is founder and president of CRISPR, and served...
21:05 , Dec 8, 2017 |  BC Week In Review  |  Financial News

ALK-Abelló raises DKK698.9M in private placement

On Dec. 7, ALK-Abelló A/S (CSE:ALK-B) raised DKK698.9 million ($111.5 million) through the sale of 1 million shares at DKK690 in an oversubscribed private placement led by Danske Bank. Other undisclosed investors also participated. ALK...
00:44 , Dec 8, 2017 |  BC Extra  |  Financial News

ALK-Abelló raises DKK698.9M

ALK-Abelló A/S (CSE:ALK-B) raised DKK698.9 million ($111.5 million) through the sale of 1 million shares at DKK690 in an oversubscribed private placement. ALK said the funds will help finance its DKK1 billion ($160 million), three-year...
19:03 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

ALK's tree allergy SLIT meets in Phase III for birch pollen allergy

In September, ALK-Abello A/S (CSE:ALK-B) reported data from a Phase III trial in 634 patients ages 12-65 with birch pollen allergic rhinitis and/or conjunctivitis showing that tree allergy sublingual immunotherapy (SLIT) met the primary endpoint...
22:53 , Nov 3, 2017 |  BC Extra  |  Company News

Management tracks: Tissue Regenix, Therapix

Regenerative medical device company Tissue Regenix Group plc (LSE:TRX) named Steve Couldwell CEO. A Tissue Regenix director since 2013, Couldwell was COO of global biosurgery at Sanofi (Euronext:SAN; NYSE:SNY). Cannabinoid company Therapix Biosciences Ltd. (Tel...
23:10 , Aug 1, 2017 |  BC Extra  |  Company News

Management tracks: Bicycle, ReNetX, ALK-Abello

Peptide company Bicycle Therapeutics Ltd. (Cambridge, U.K.) named Lee Kalowski CFO. He was CFO of Tokai Pharmaceuticals Inc. , which merged with Otic Pharma Ltd. to form Novus Therapeutics Inc. (NASDAQ:NVUS). Neurology play ReNetX Bio...
21:48 , Apr 20, 2017 |  BC Week In Review  |  Clinical News

Acarizax regulatory update

ALK-Abello’s Acarizax HDM SLIT tablets received expanded approval in 12 European countries to treat HDM-induced allergic rhinitis in patients ages 12-17. The countries are Austria, Czech Republic, Denmark, Finland, Italy, the Netherlands, Norway, Poland, Sweden,...
21:07 , Apr 6, 2017 |  BC Week In Review  |  Clinical News

Miticure regulatory update

ALK-Abello said Torii submitted a regulatory application in Japan to expand the label of Miticure to include patients with pediatric house dust mite (HDM)-induced allergic rhinitis. The HDM sublingual immunotherapy (SLIT) product is approved in...
19:39 , Mar 10, 2017 |  BC Week In Review  |  Clinical News

House dust mite (HDM) sublingual allergy immunotherapy (SLIT) regulatory update

FDA approved a BLA for ALK-Abello’s HDM SLIT to treat HDM-induced rhinitis with or without conjunctivitis. ALK-Abello said the launch of the immunotherapy is “likely looking towards 2018.” Last year, ALK-Abello regained North American rights...